Clinical and in vitro evaluation of cephapirin: a new parenteral cephalosporin

S. Bodner,M. Koenig
DOI: https://doi.org/10.1097/00000441-197201000-00007
1972-01-01
Abstract:Cephapirin, a new semisynthetic cephalosporin antibiotic for parenteral use was evaluated in vitro and in patients with severe bacterial infections. Strains of Staphylococcus aureus, Group A streptococci, Diplococcus pneumoniae, Proteus mirabilis, Escherichia coli, Klebsiella pneumoniae, pseudomonas, and salmonella were tested in vitro and were found to have the same degree of sensitivity to cephapirin as to cephalothin, with the exception of Group A streptococci and pneumococci which appeared more sensitive to cephapirin. Seven of 10 patients treated were cured clinically and bacteriologically, and in one instance the outcome was indeterminate. Side effects were minimal. One patient developed mild eosinophilia after high dose therapy for six weeks. There was little pain and no phlebitis at the injection or infusion sites. There was no evidence of renal toxicity even after prolonged therapy at high dosage. Serum and urine concentrations of cephapirin were similar to those achieved with equivalent doses of currently available parenteral cephalosporins.
What problem does this paper attempt to address?